The combination of the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (DAC) and the chemotherapeutic agent paclitaxel was found to enhance LEF1 suppression and attenuate tumor growth in renal cell carcinoma (RCC) cells with high levels of LEF1 expression [29]. Here, LEF1 is linked to neoplasm.